Search results for "apheresi"

showing 10 items of 61 documents

Therapeutic Plasmapheresis with Albumin Replacement in Alzheimer’s Disease and Chronic Progressive Multiple Sclerosis: A Review

2020

Background: Reducing the burden of beta-amyloid accumulation and toxic autoimmunity-related proteins, one of the recognized pathophysiological markers of chronic and common neurological disorders such as Alzheimer’s disease (AD) and multiple sclerosis (MS), may be a valid alternative therapy to reduce their accumulation in the brain and thus reduce the progression of these disorders. The objective of this review was to evaluate the efficacy of plasmapheresis (PP) in AD and chronic progressive MS patients (in terms of improving clinical symptoms) and to analyze its safety and protocols. Methods: Articles related to this topic and published without time limitations in the Medline, and C…

0301 basic medicineOncologymedicine.medical_specialtyAmyloid betamedicine.medical_treatmentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441DiseaseReviewlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineVerbal fluency testDementiamagnetic resonance imagingauto-immunityalbuminbiologybusiness.industryMultiple sclerosislcsh:Rmedicine.diseasePathophysiologyamyloid beta030104 developmental biologyplasmapheresisToxicitybiology.proteinMolecular MedicinePlasmapheresisbusiness030217 neurology & neurosurgerydementiaPharmaceuticals
researchProduct

The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency

2017

International audience; A good understanding of the natural history of rare genetic lipid disorders is a pre-requisite for successful patient management. Disease registries have been helpful in this regard. Lipoprotein Lipase Deficiency (LPLD) is a rare, autosomal-recessive lipid disorder characterized by severe hypertriglyceridemia and a very high risk for recurrent acute pancreatitis, however, only limited data are available on its natural course. Alipogene tiparvovec (Glybera (R)) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency), a 15-year registry focusing on LPLD was launched in …

0301 basic medicinePediatricsPathologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]Familial hypercholesterolemiaDisease030204 cardiovascular system & hematologyGeneTHERAPY0302 clinical medicineFamilialRisk FactorsHyperchylomicronemiaAlipogene tiparvovecRegistriesFAMILIAL HYPERCHOLESTEROLEMIAmedia_commonHypertriglyceridemiaPrognosis3. Good healthNatural historySystematic reviewPhenotypeDISEASESSAFETYHyperlipoproteinemia Type ICardiology and Cardiovascular Medicinemedicine.medical_specialtyAPHERESISRegistryFamilial chylomicronemia syndromeGENIALLLysosomal acid lipase deficiencyLipid Metabolism Inborn Errors03 medical and health sciencesLipoprotein lipase deficiencyRare DiseasesGene therapychylomicronemia syndromemedicinemedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseEuropean unionLipoprotein lipase deficiency (LPLD)business.industryALIPOGENE TIPARVOVEC AAV1-LPLS447Xmedicine.diseaseAlipogene tiparvovecLipoprotein Lipase030104 developmental biologyOrphan diseasebusiness
researchProduct

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19

2021

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)LipoproteinsEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Familial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicinePandemicInternal MedicinemedicineHumansHyperlipoproteinemia Type IILife StylePandemicsLetter to the Editor030304 developmental biology0303 health sciencesNutrition and DieteticsSARS-CoV-2Life stylebusiness.industryHomozygoteCOVID-19medicine.diseaseImmunologyBlood Component RemovalCardiology and Cardiovascular MedicinebusinessLipoprotein apheresisJournal of Clinical Lipidology
researchProduct

Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis

2013

Depletion of naive T cells from donor leukapheresis products (LPs) aims at the reduction of alloreactivity, while preserving memory T-cell reactivity (for example, to pathogens). This study established the immunomagnetic depletion procedure under clean room conditions using CD45RA beads and analyzed LPs of six donors for cell composition and functional immune responses. CD45RA depletion resulted in 3.4-4.7 log (median 4.4) reduction of CD45RA(+) T cells, thereby eliminating naive and late effector T cells. B cells were also completely removed, whereas significant proportions of NK cells, monocytes and granulocytes persisted. CD45RA-depleted LPs contained effector and central memory CD4(+) a…

AdultCD4-Positive T-LymphocytesMaleHerpesvirus 4 HumanT-LymphocytesCytomegalovirusGraft vs Host DiseaseEnzyme-Linked Immunosorbent AssayCD8-Positive T-LymphocytesLymphocyte DepletionImmunophenotypingInterferon-gammaInterleukin 21ImmunophenotypingImmune systemAntigenAntigens NeoplasmHumansMedicineLeukapheresisCandidaTransplantationImmunomagnetic Separationbusiness.industryHematologyLeukapheresisFlow Cytometrymedicine.diseaseTransplantationAspergillusGraft-versus-host diseaseImmunologyLeukocyte Common AntigensbusinessCD8Bone Marrow Transplantation
researchProduct

Sequential analysis of CD34+ and CD34− cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plu…

2001

Administration of stem cell factor (SCF) has been proven to enhance cytokine-induced mobilization of CD34+ hematopoietic progenitor cells (HPC) into the peripheral blood (PB). The aim of the present study was to explore in a homogeneous group of 22 uniformly treated breast cancer patients: (1) the kinetics of mobilization into PB of both CD34+ and CD34- cell subsets, including dendritic cells, in sequential samples obtained from day +7 up to day +12 after mobilization; and (2) the composition of the CD34+ and CD34- cell subsets present in the two leukapheresis products obtained for each patient. The following CD34+ and CD34- subsets were analyzed: early CD34+ HPC, erythroid-, myeloid- and B…

AdultCancer ResearchAdolescentCD14CD34Antigens CD34Breast NeoplasmsStem cell factorBiologyImmunophenotypingGranulocyte Colony-Stimulating FactorHumansLeukapheresisAntigen-presenting cellCyclophosphamideHematopoietic Stem Cell MobilizationAgedStem Cell FactorHematologyDendritic cellLeukapheresisMiddle AgedMolecular biologyHematopoietic Stem Cell MobilizationRecombinant ProteinsGranulocyte colony-stimulating factorOncologyImmunologyFemaleLeukemia
researchProduct

Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience

2006

BACKGROUND:  In contrast to other extracorporeal treatments no established regime exists for anticoagulation with low-molecular-weight heparin (LMWH) in plasmapheresis therapy. A study was conducted to investigate whether LMWH (dalteparin-Na) is suitable as an effective anticoagulant in plasmapheresis therapy. STUDY DESIGN AND METHODS:  Eleven patients with autoimmune neurological diseases and the necessity for a plasmapheresis therapy were enrolled. A capillary membrane filter was used. A total of 2000 mL of human plasma was isovolumetrically exchanged per plasmapheresis cycle. The anticoagulation was accomplished with a single bolus of LMWH (dalteparin) of 80 to 90 IU per kg of body weigh…

AdultDalteparinmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentImmunologyLow molecular weight heparinGuillain-Barre SyndromeExtracorporealBolus (medicine)Myasthenia GravismedicineHumansImmunology and AllergyMonitoring PhysiologicDalteparin sodiumbusiness.industryAnticoagulantAnticoagulantsPlasmapheresisHematologyHeparinSurgerySingle bolusAnesthesiaPlasmapheresisbusinessmedicine.drugTransfusion
researchProduct

Albumin versus solvent/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertrig…

2015

Chylomicronemia syndrome is a metabolic condition characterized by severe fasting hypertrigliceridemia (≥ 1000 mg/dL) and other clinical features including chronic abdominal pain and recurrent acute pancreatitis. In patients with acute or recurrent pancreatitis, plasma exchange (PEx) is indicated for the treatment of acute disease and prevention of recurrence. The use of plasma instead of albumin as replacement fluid has been suggested for its putative ability to replace the deficient enzyme possibly leading to better clinical improvement.A 40-year-old man with chylomicronemia syndrome due to a newly identified loss-of-function mutation in the lipoprotein lipase (LPL) gene (IVS2, c.250-1G/C…

AdultHypertriglyceridemiaMaleSettore MED/09 - Medicina InternaPancreatitisAlbuminsplasma exchangeDetergentsHumansPlasmapheresisLPLtriglycerides
researchProduct

Worldwide experience of homozygous familial hypercholesterolaemia:retrospective cohort study

2022

[Background]: Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Current guidance about its management and prognosis stems from small studies, mostly from high-income countries. The objective of this study was to assess the clinical and genetic characteristics, as well as the impact, of current practice on health outcomes of HoFH patients globally.

AdultMaleHomozygous Familial HypercholesterolemiaAdolescentretrospective studyCHILDRENDoenças Cardio e Cérebro-vascularesCohort StudiesYoung AdultMedicine General & InternalGeneral & Internal MedicineCardiovascular DiseaseHumansRegistriesLIPOPROTEIN-APHERESISChild11 Medical and Health SciencesRetrospective StudiesHomozygous Familial Hypercholesterolaemia International Clinical CollaboratorsScience & TechnologyGUIDANCEclinical characteristicEVOLOCUMABHomozygous familial hypercholesterolemia; Worldwide; Therapies; Cardiovascular diseaseGeneral MedicineCARECardiovascular diseaseOPEN-LABELEFFICACYINSIGHTSTherapiesChild PreschooloutcomeFemalegeneticFamilial HypercholesterolaemiaLife Sciences & BiomedicineWorldwide
researchProduct

The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood.

2005

Background There exists a current lack of information about the composition of the different types of plasma. No direct comparisons between apheresis plasma (AP) and recovered plasma (RP) derived from in-line-filtered whole blood (WB) have been published to date. Study design and methods Sixty AP units, 100 RP units from in-line-filtered WB held for 3 hours at 20 degrees C between donation and freezing, and an additional 100 RP units held for 15 hours at 20 degrees C before freezing were analyzed for coagulation factors and inhibitors, total protein, immunoglobulin G (IgG), and hemostasis and proteolysis activation markers. The influence of twice freezing and thawing on clotting factors V, …

AdultMaleImmunologyProtein SImmunoglobulin GCitric AcidAndrologyFactor IXLeukocyte CountPlasmaImmunology and AllergyHumansFactor XIWhole bloodClotting factorHemostasisFactor VIIIbiologyChemistryAnticoagulantsFactor VFibrinogenHematologyMiddle AgedApheresisCoagulationHemostasisImmunologybiology.proteinBlood Component RemovalFemaleLeukocyte ElastasePlatelet factor 4Transfusion
researchProduct

Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia

1995

Hypercholesterolemia has been recognised as a primary risk factor for coronary heart disease. Reduction of plasma levels of total and LDL cholesterol has been shown to decrease coronary atherosclerosis. Plasmapheresis represents an useful non-pharmacological tool to treat severe hypercholesterolemias. We have evaluated the effectiveness of a system of plasmapheresis using a cascade filtration method in two young male subjects (aged 16 and 26 years) with homozygous familial hypercholesterolemia. Both showed severe coronary atherosclerosis as determined by angiography. Procedures were performed at intervals of 7 days in each case. We observed a mean reduction of plasma levels of total cholest…

AdultMalemedicine.medical_specialtyAdolescentApolipoprotein Bmedicine.medical_treatmentFamilial hypercholesterolemiaFibrinogenGastroenterologyHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineHumansHyperlipoproteinemia Type IIRisk factorCoronary atherosclerosisbiologybusiness.industryCholesterolCholesterol LDLPlasmapheresisHematologyGeneral Medicinemedicine.diseaseEndocrinologychemistrybiology.proteinlipids (amino acids peptides and proteins)PlasmapheresisbusinessFiltrationmedicine.drugJournal of Clinical Apheresis
researchProduct